Tsubota Laboratory Incorporated
Interim Earnings Presentation for the Fiscal Year Ending March 2027
For the interim period of the fiscal year ending March 2027, Tsubota Laboratory Incorporated reported revenue of 4.41 hundred million yen (YoY +3.39 hundred million yen), operating loss of -295 million yen, ordinary loss of -259 million yen, and interim net loss of -260 million yen. The company aims to return to profitability in the second half through milestone payments under existing contracts and new licensing agreements. Consolidation of Mediproduce as a subsidiary strengthens the business base. Full-year guidance for the current fiscal year anticipates revenue of 1,400–1,800 million yen, operating profit of 0–45 million yen, ordinary profit of 40–85 million yen, and net profit of 40–85 million yen (including 9 months). Major pipeline progress includes clinical advancement of TLM-001/TLM-003 and preparations for China expansion and additional trials for TLG-001/TLG-003. The company plans to secure funding via stock options up to approximately 2,000 million yen to be allocated to clinical development, licensing-in, and new businesses.
Key Figures
- Revenue (interim): 4.41 hundred million yen
- Interim Net Income: -2.60 hundred million yen
- Cash and Cash Equivalents: 11.86 hundred million yen
AI要約
Overview of Performance
For the interim period, Tsubota Laboratory Incorporated reported standalone revenue of 4.41 hundred million yen, driven by a recovery in license revenues. However, the company recorded an operating loss of -295 million yen, and ordinary and interim net losses continued. The consolidation of Mediproduce as a subsidiary has diversified the revenue structure and strengthened the business base. The company aims to achieve full-year profitability in the second half through milestone payments from existing contracts and progress in new licensing agreements. R&D expenditure will continue to be invested.
Outlook and Funding
As of the end of September, cash and equivalents stood at 11.86 hundred million yen. The company has an overdraft facility of 1,000 million yen and has set stock options up to approximately 2,000 million yen. The second-half outlook assumes consolidated revenue (Tsubota Laboratory Incorporated plus Mediproduce) of 1,400–1,800 million yen, operating income of 0–45 million yen, ordinary income of 40–85 million yen, and interim net income of 40–85 million yen. Funds will be allocated to clinical development, licensing-in activities, and new business initiatives.
Revenue Trend
Operating Income Trend
Interim Net Income Trend
Cash Balance Trend
Borrowings Balance Trend
Tsubota Laboratory Incorporated
Company overview · Stock price · Financial data · All IR
